GO
Loading...

Perrigo Co

More

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, saying it was too low and calling Teva stock an "unacceptable" currency. Mylan, which is pursuing its own takeover of Perrigo Co Plc, had been expected to reject the offer after having indicated that such a combination would not be a good fit.

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, but left the door open for talks. Mylan also said it remained committed to its offer for Perrigo Co Plc. Last week, Mylan said it would take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profile...

  • Mylan rejects Teva's $40.1 billion buyout offer Monday, 27 Apr 2015 | 9:58 AM ET

    NEW YORK— Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan is trying to buy Perrigo Co. of Ireland for about $30 billion in cash and stock, combining its own generic drug business with Perrigo's position in over-the-counter medications and other nonprescription...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • NEW YORK— Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low.

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • April 22- Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV. Meanwhile, Canonsburg, Pennsylvania- based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter...

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • DUBLIN— Irish drug and over-the-counter ingredients maker Perrigo Co. said Tuesday it took a loss in its fiscal third quarter as it prepared to buy a Belgian competitor. Perrigo's fiscal third quarter ended on March 28, and the company closed its $4.48 billion purchase of Omega Pharma on March 30. Perrigo said Tuesday that that offer is too low because it doesn't...

  • NEW YORK— Over-the-counter medicines maker Perrigo said Tuesday it is turning down a buyout offer from generic drugmaker Mylan that valued the company at $205 per share, or almost $29 billion, because it's too low. Perrigo said that Mylan's offer undervalues its business, including its product pipeline and its recent purchase of Belgium's Omega Pharma, one of...

  • Perrigo rejects $205/share bid from Mylan Tuesday, 21 Apr 2015 | 4:26 PM ET

    April 21- Dublin- based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company. Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros acquisition of Omega Pharma and new products that are expected to generate about $1...

  • April 21- Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and...

  • TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. on Tuesday proposed buying smaller rival Mylan for $40 billion, saying it was a better deal than Mylan's alternate offer to buy Perrigo Co. Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the...

  • Teva offers to buy Mylan in $40.1B cash-and-stock deal Tuesday, 21 Apr 2015 | 9:14 AM ET

    TRENTON, N.J.— Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators. If Israel- based Teva Pharmaceutical Industries Ltd. succeeded, the combination would...

  • Asian stocks mostly higher as Japan exports improve Tuesday, 21 Apr 2015 | 12:31 AM ET

    TAKING IT ALL IN: "It seems the market is in a holding pattern as investors are waiting to see just how much the dollar impacts corporate earnings," said Russell Price, Ameriprise Financial's senior economist. The chemical giant also lowered its forecast for full-year profits, and its stock fell $2.15, or 3 percent, to $70.70. CLEANING UP: Kimberly-Clark jumped 4...

  • NYSE stocks posting largest volume increases Friday, 17 Apr 2015 | 6:13 PM ET

    NEW YORK— A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:. The shares fell $1.70 or 7.7 percent to $20.29. Celanese Corp.: Approximately 6,642,500 shares changed hands, a 577.1 percent increase over its 65- day average volume.

  • Shares of Mylan NV rose $2.98, or 4.5 percent, to $69.82. Earlier this month Mylan offered to buy generic drug and ingredients maker Perrigo for about $29 billion, or $205 per share. Perrigo, which is based in Ireland, said it would review Mylan's offer.

  • Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva. Mylan Executive Chairman and former Chief Executive Officer Robert Coury said the Perrigo plans remain on track. "Mylan is fully committed to its stand-alone strategy, including its proposal...

  • Teva considering potential bid for Mylan - Bloomberg Friday, 17 Apr 2015 | 2:37 PM ET

    April 17- Teva Pharmaceuticals Industries is considering a bid for Mylan NV, Bloomberg reported, citing people familiar with the matter. Teva has not made a formal approach, Bloomberg reported. Generic drugmaker Mylan offered to buy Perrigo Co Plc for about $29 billion in cash and stock in early April.

  • Deals this week, the busiest so far this year, were worth $140 billion, lifting year-to-date M&A activity to almost $1 trillion, according to Thomson Reuters data. It worked for Mylan on its offer for Perrigo, BG Group in its takeover by Shell, TNT Express in its $4.3 billion bid from Fedex and Permira Advisers and the Canada Pension Plan Investment Board in its...